One moment
We’re getting things ready for you.
What happens next
A calm, online process
Treatment availability depends on eligibility and clinician review. Nothing on this page guarantees prescribing, approval, or specific outcomes.
Complete your intake
A short intake captures the context your provider needs to review your file.
Clinician chart review
A licensed clinician reviews your information and approves, requests more, or declines treatment.
Discreet fulfillment
When prescribed, fulfillment is handled through the partnered pharmacy with discreet packaging.
Treatment is determined by a licensed clinician after review. Not all patients are candidates. Individual results vary.
About PT-141
What it is, how it works, what it's studied for, and safety considerations.
What Is PT-141?
PT-141 is another name for bremelanotide, a melanocortin receptor agonist. FDA-approved Vyleesi (bremelanotide) is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women when low desire is not due to a medical/psychiatric condition, relationship problem, or medication/substance. Off-label use or compounded versions require careful provider review.
How It Works
Bremelanotide acts centrally through melanocortin receptor pathways involved in sexual desire signaling. It is different from PDE-5 inhibitors such as sildenafil because it is not primarily a blood-flow medication. The FDA-approved product is specifically indicated for HSDD in a defined population.
What It’s Studied For
Bremelanotide was studied in HSDD clinical trials and has FDA labeling for indication, dosing, contraindications, and safety warnings. It has also been discussed off-label in other sexual-wellness contexts; FDA-approved indications are distinguished from provider-determined off-label use.
How It May Be Used in a Clinician-Supervised Program
A licensed clinician may consider PT-141 after reviewing low desire concerns, cardiovascular health, blood pressure, medications, pregnancy status, psychiatric history, relationship factors, hormone status where relevant, and whether low desire may be secondary to another condition or drug. The provider may determine it is not appropriate.
Preferred Starting Options / Dosing Notes
Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.
Average starting option
- 10 mg
Available options
- 10 mg
Provider note: Do not change dose, frequency, or route of use unless directed by your clinician.
Safety Considerations
- Transient blood pressure increases and heart-rate decrease.
- Contraindication in uncontrolled hypertension or known cardiovascular disease.
- Nausea, flushing, headache, vomiting, and injection-site reactions.
- Possible focal hyperpigmentation with repeated use.
- Disclose cardiovascular disease, hypertension, kidney/liver disease, pregnancy plans, and all medications.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.
Frequently Asked Questions
Is PT-141 guaranteed to be prescribed?
No. Prescriptions are never guaranteed. A licensed clinician reviews your medical intake and determines whether treatment is medically appropriate.
Can my provider change my treatment or dose?
Yes. Your selected treatment and preferred starting option are treated as preferences. Your provider may approve your selection, recommend a different option, adjust dosing, request more information, or deny treatment.
Does payment guarantee treatment?
No. Payment does not guarantee approval, a prescription, a specific medication, or a specific dose.
How is PT-141 used?
Use instructions are provided only if treatment is prescribed. If prescribed, follow your clinician's dosing and administration instructions exactly.
Are compounded medications FDA-approved?
No. Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved and are not evaluated by FDA for safety, effectiveness, or quality before marketing.
What comes with injectable treatments if prescribed?
When prescribed by a licensed clinician, injectable peptide treatments may ship with syringes, prep pads for sterilization, and an instructions and dosing guide. Use only as directed by your clinician.
Disclaimer
Although the information on this page is based on available educational research and product information, it is provided for informational purposes only and is not medical advice. Treatment decisions, medication selection, dosing, and eligibility are determined by a licensed clinician after review. Not all patients are candidates, and individual results may vary. Use medications only as directed by your clinician.
Important safety information
This page is informational and does not replace medical advice from a licensed professional. Treatment availability depends on eligibility, clinician review, and applicable requirements. ElliotMeds does not provide emergency medical services — if you are experiencing a medical emergency, call 911 or go to the nearest emergency room.
Related treatments
Other clinician-reviewed treatments related to PT-141.
See our other treatments
Explore other clinician-reviewed treatment programs.
